Validation of novel optical imaging technologies: The pathologists' view

Wendy A. Wells, Peter E. Barker, Calum MacAulay, Marco Novelli, Richard M Levenson, James M. Crawford

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Noninvasive optical imaging technology has the potential to improve the accuracy of disease detection and predict treatment response. Pathology provides the critical link between the biological basis of an image or spectral signature and clinical outcomes obtained through optical imaging. The validation of optical images and spectra requires both morphologic diagnosis from histopathology and parametric analysis of tissue features above and beyond the declared pathologic "diagnosis." Enhancement of optical imaging modalities with exogenously applied biomarkers also requires validation of the biological basis for molecular contrast. For an optical diagnostic or prognostic technology to be useful, it must be clinically important, independently informative, and of demonstrated beneficial value to patient care. Its usage must be standardized with regard to methods, interpretation, reproducibility, and reporting, in which the pathologist plays a key role. By providing insight into disease pathobiology, interpretive or quantitative analysis of tissue material, and expertise in molecular diagnosis, the pathologist should be an integral part of any team that is validating novel optical imaging modalities. This review will consider (1) the selection of validation biomarkers; (2) standardization in tissue processing, diagnosis, reporting, and quantitative analysis; (3) the role of the pathologist in study design; and (4) reference standards, controls, and interobserver variability.

Original languageEnglish (US)
Article number051801
JournalJournal of Biomedical Optics
Volume12
Issue number5
DOIs
StatePublished - 2007
Externally publishedYes

Fingerprint

Optical Imaging
Technology
Imaging techniques
biomarkers
Biomarkers
Tissue
quantitative analysis
Observer Variation
spectral signatures
standardization
pathology
Pathology
Chemical analysis
Standardization
optical spectrum
Patient Care
signatures
Pathologists
augmentation
Processing

Keywords

  • Biomarker
  • Interobserver variation
  • Optical imaging
  • Pathology
  • Standardization
  • Validation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Clinical Biochemistry
  • Atomic and Molecular Physics, and Optics
  • Biomedical Engineering
  • Biomaterials
  • Electronic, Optical and Magnetic Materials

Cite this

Wells, W. A., Barker, P. E., MacAulay, C., Novelli, M., Levenson, R. M., & Crawford, J. M. (2007). Validation of novel optical imaging technologies: The pathologists' view. Journal of Biomedical Optics, 12(5), [051801]. https://doi.org/10.1117/1.2795569

Validation of novel optical imaging technologies : The pathologists' view. / Wells, Wendy A.; Barker, Peter E.; MacAulay, Calum; Novelli, Marco; Levenson, Richard M; Crawford, James M.

In: Journal of Biomedical Optics, Vol. 12, No. 5, 051801, 2007.

Research output: Contribution to journalArticle

Wells, WA, Barker, PE, MacAulay, C, Novelli, M, Levenson, RM & Crawford, JM 2007, 'Validation of novel optical imaging technologies: The pathologists' view', Journal of Biomedical Optics, vol. 12, no. 5, 051801. https://doi.org/10.1117/1.2795569
Wells, Wendy A. ; Barker, Peter E. ; MacAulay, Calum ; Novelli, Marco ; Levenson, Richard M ; Crawford, James M. / Validation of novel optical imaging technologies : The pathologists' view. In: Journal of Biomedical Optics. 2007 ; Vol. 12, No. 5.
@article{28d9ef072e724db1842f057f4812fe95,
title = "Validation of novel optical imaging technologies: The pathologists' view",
abstract = "Noninvasive optical imaging technology has the potential to improve the accuracy of disease detection and predict treatment response. Pathology provides the critical link between the biological basis of an image or spectral signature and clinical outcomes obtained through optical imaging. The validation of optical images and spectra requires both morphologic diagnosis from histopathology and parametric analysis of tissue features above and beyond the declared pathologic {"}diagnosis.{"} Enhancement of optical imaging modalities with exogenously applied biomarkers also requires validation of the biological basis for molecular contrast. For an optical diagnostic or prognostic technology to be useful, it must be clinically important, independently informative, and of demonstrated beneficial value to patient care. Its usage must be standardized with regard to methods, interpretation, reproducibility, and reporting, in which the pathologist plays a key role. By providing insight into disease pathobiology, interpretive or quantitative analysis of tissue material, and expertise in molecular diagnosis, the pathologist should be an integral part of any team that is validating novel optical imaging modalities. This review will consider (1) the selection of validation biomarkers; (2) standardization in tissue processing, diagnosis, reporting, and quantitative analysis; (3) the role of the pathologist in study design; and (4) reference standards, controls, and interobserver variability.",
keywords = "Biomarker, Interobserver variation, Optical imaging, Pathology, Standardization, Validation",
author = "Wells, {Wendy A.} and Barker, {Peter E.} and Calum MacAulay and Marco Novelli and Levenson, {Richard M} and Crawford, {James M.}",
year = "2007",
doi = "10.1117/1.2795569",
language = "English (US)",
volume = "12",
journal = "Journal of Biomedical Optics",
issn = "1083-3668",
publisher = "SPIE",
number = "5",

}

TY - JOUR

T1 - Validation of novel optical imaging technologies

T2 - The pathologists' view

AU - Wells, Wendy A.

AU - Barker, Peter E.

AU - MacAulay, Calum

AU - Novelli, Marco

AU - Levenson, Richard M

AU - Crawford, James M.

PY - 2007

Y1 - 2007

N2 - Noninvasive optical imaging technology has the potential to improve the accuracy of disease detection and predict treatment response. Pathology provides the critical link between the biological basis of an image or spectral signature and clinical outcomes obtained through optical imaging. The validation of optical images and spectra requires both morphologic diagnosis from histopathology and parametric analysis of tissue features above and beyond the declared pathologic "diagnosis." Enhancement of optical imaging modalities with exogenously applied biomarkers also requires validation of the biological basis for molecular contrast. For an optical diagnostic or prognostic technology to be useful, it must be clinically important, independently informative, and of demonstrated beneficial value to patient care. Its usage must be standardized with regard to methods, interpretation, reproducibility, and reporting, in which the pathologist plays a key role. By providing insight into disease pathobiology, interpretive or quantitative analysis of tissue material, and expertise in molecular diagnosis, the pathologist should be an integral part of any team that is validating novel optical imaging modalities. This review will consider (1) the selection of validation biomarkers; (2) standardization in tissue processing, diagnosis, reporting, and quantitative analysis; (3) the role of the pathologist in study design; and (4) reference standards, controls, and interobserver variability.

AB - Noninvasive optical imaging technology has the potential to improve the accuracy of disease detection and predict treatment response. Pathology provides the critical link between the biological basis of an image or spectral signature and clinical outcomes obtained through optical imaging. The validation of optical images and spectra requires both morphologic diagnosis from histopathology and parametric analysis of tissue features above and beyond the declared pathologic "diagnosis." Enhancement of optical imaging modalities with exogenously applied biomarkers also requires validation of the biological basis for molecular contrast. For an optical diagnostic or prognostic technology to be useful, it must be clinically important, independently informative, and of demonstrated beneficial value to patient care. Its usage must be standardized with regard to methods, interpretation, reproducibility, and reporting, in which the pathologist plays a key role. By providing insight into disease pathobiology, interpretive or quantitative analysis of tissue material, and expertise in molecular diagnosis, the pathologist should be an integral part of any team that is validating novel optical imaging modalities. This review will consider (1) the selection of validation biomarkers; (2) standardization in tissue processing, diagnosis, reporting, and quantitative analysis; (3) the role of the pathologist in study design; and (4) reference standards, controls, and interobserver variability.

KW - Biomarker

KW - Interobserver variation

KW - Optical imaging

KW - Pathology

KW - Standardization

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=34247381860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247381860&partnerID=8YFLogxK

U2 - 10.1117/1.2795569

DO - 10.1117/1.2795569

M3 - Article

C2 - 17994879

AN - SCOPUS:34247381860

VL - 12

JO - Journal of Biomedical Optics

JF - Journal of Biomedical Optics

SN - 1083-3668

IS - 5

M1 - 051801

ER -